These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17240253)

  • 21. Time-lapse imaging of retinal angiogenesis reveals decreased development and progression of neovascular sprouting by anecortave desacetate.
    Unoki N; Murakami T; Ogino K; Nukada M; Yoshimura N
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2347-55. PubMed ID: 19959648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiostatic and angiogenic factors.
    de Groot H; Schmit-Eilenberger V; Kirchhof J; Augustin AJ
    Dev Ophthalmol; 2010; 46():1-3. PubMed ID: 20703028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical safety profile of posterior juxtascleral depot administration of anecortave acetate 15 mg suspension as primary therapy or adjunctive therapy with photodynamic therapy for treatment of wet age-related macular degeneration.
    Regillo CD; D'Amico DJ; Mieler WF; Schneebaum C; Beasley CH; Sullins GT
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S70-8. PubMed ID: 17240259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
    Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD
    Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?
    Lippi G; Favaloro EJ
    Semin Thromb Hemost; 2010 Jul; 36(5):558-69. PubMed ID: 20632253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.
    Dorrell MI; Aguilar E; Scheppke L; Barnett FH; Friedlander M
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):967-72. PubMed ID: 17210921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and development of polymer conjugates as anti-angiogenic agents.
    Segal E; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-angiogenic function of tocotrienol.
    Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T
    Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of angiostatic steroid with or without glucocorticoid activity on metastasis.
    Sakamoto N; Tanaka NG
    Invasion Metastasis; 1987; 7(4):208-16. PubMed ID: 2444551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study.
    Klais CM; Eandi CM; Ober MD; Sorenson JA; Sadeghi SN; Freund KB; Spaide RF; Slakter JS; Yannuzzi LA
    Retina; 2006 Sep; 26(7):773-9. PubMed ID: 16963850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate.
    Clark AF; Mellon J; Li XY; Ma D; Leher H; Apte R; Alizadeh H; Hegde S; McLenaghan A; Mayhew E; D'Orazio TJ; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2158-62. PubMed ID: 10440274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.
    Bahramsoltani M; Plendl J
    APMIS; 2007 Jan; 115(1):30-46. PubMed ID: 17223849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-angiogenic activity of the purine analog 6-thioguanine.
    Presta M; Belleri M; Vacca A; Ribatti D
    Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes.
    Jockovich ME; Murray TG; Clifford PD; Moshfeghi AA
    Retina; 2007 Feb; 27(2):247-52. PubMed ID: 17290209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pigment epithelium-derived factor (PEDF): drug developmental challenges ahead for a budding anti-angiogenic.
    Dass CR; Choong PF
    Pharmazie; 2008 Jan; 63(1):4-6. PubMed ID: 18271294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and development of anti-angiogenic peptides: A structural link.
    Dings RP; Nesmelova I; Griffioen AW; Mayo KH
    Angiogenesis; 2003; 6(2):83-91. PubMed ID: 14739615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel function of ascorbic acid as an angiostatic factor.
    Ashino H; Shimamura M; Nakajima H; Dombou M; Kawanaka S; Oikawa T; Iwaguchi T; Kawashima S
    Angiogenesis; 2003; 6(4):259-69. PubMed ID: 15166494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment.
    Missel P; Chastain J; Mitra A; Kompella U; Kansara V; Duvvuri S; Amrite A; Cheruvu N
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):137-46. PubMed ID: 20415622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
    Mallery SR; Morse MA; Wilson RF; Pei P; Ness GM; Bradburn JE; Renner RJ; Schuller DE; Robertson FM
    J Cell Biochem; 2003 May; 89(1):133-43. PubMed ID: 12682914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.